Valneva Cuts Workforce Amid Revenue Drop, Bets Big on Lyme Vaccine

Valneva, a French biopharmaceutical company specializing in vaccine development, is navigating a period of significant challenge and transformation. The firm announced around mid-May 2026 that it would reduce its global workforce by 10% to 15%, impacting up to 674 employees across its operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States.

This decision follows a difficult first quarter in 2026, where Valneva reported a substantial nearly 40% drop in total revenues, falling to €30.9 million from €49.2 million in the same period of 2025. The company attributed this financial downturn to several factors, including a strategic wind-down of its third-party vaccine distribution business, adjustments in military delivery schedules, and an "emerging adverse trend in travel vaccine uptake across key markets, driven by geopolitical factors."

The workforce reduction is a key component of a broader restructuring plan initiated in April 2026. This comprehensive strategy aims to streamline global business operations and achieve a significant 25% to 35% reduction in 2026 operating expenses compared to 2025 levels, with a notable portion of these savings expected from research and development spending. This follows an earlier consolidation effort in late 2025, which saw the closure of a preclinical R&D site in Nantes, France, affecting 30 employees, and the centralization of all French operations in Lyon, with R&D activities consolidated in Vienna, Austria.

Amid these financial pressures, Valneva's primary hope for future revenue and stability rests on its Lyme disease vaccine candidate, VLA15. This investigational vaccine is being co-developed with pharmaceutical giant Pfizer, a partnership that began on April 30, 2020. Pfizer further solidified its commitment in June 2022 by investing €90.5 million, equivalent to $95 million, in Valneva, acquiring an 8.1% stake in the company's share capital. This investment was intended to support Valneva's financial contribution to the Phase 3 development of the Lyme disease program, increasing Valneva's funding share of remaining shared development costs from 30% to 40%.

VLA15, also known by its development codes PF-07307405 or LB6V, is a 6-valent OspA-based multivalent protein subunit vaccine designed to target the six most prevalent *Borrelia burgdorferi* serotypes found in North America and Europe. The U.S. Food and Drug Administration (FDA) recognized the vaccine's potential by granting it Fast Track designation in July 2017. The pivotal Phase 3 VALOR (Vaccine Against Lyme for Outdoor Recreationists) clinical trial, identified as NCT05477524, commenced in August 2022. It enrolled individuals aged five years and older in Lyme disease-endemic regions across the U.S., Canada, and Europe, with participants completing the primary vaccination series of three doses by July 17, 2024.

Topline results from the Phase 3 VALOR trial were announced on March 23, 2026, indicating over 70% efficacy in preventing Lyme disease in individuals aged five years and above. Specifically, reported efficacies were 73.2% from 28 days post-dose 4 and 74.8% from 1-day post-dose 4. However, the trial did not meet a predetermined 95% confidence interval for its primary endpoint, a factor Pfizer attributed to a lower-than-anticipated number of Lyme disease cases accruing during the study period. Despite this, Pfizer expressed confidence in the vaccine's potential.

Peter Bühler, Valneva's Chief Financial Officer, commented on the first-quarter sales, stating that they "reflect the sharp decline in third-party products and our planned focus on proprietary products. We also see the first indications of the geopolitical situation adversely affecting travel." He further added, "We continued to reduce our operating cash burn meaningfully and, combined with further cost saving measures and our strengthened balance sheet following the successful financing completed in April, we expect a solid cash position through the potential regulatory approvals of our Lyme disease vaccine."

Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer at Pfizer, remarked on the trial results, stating, "The efficacy shown in the VALOR study of more than 70% is highly encouraging and creates confidence in the vaccine's potential to protect against this disease that can be debilitating." Valneva's CEO, Thomas Lingelbach, also acknowledged the progress, noting, "These results bring us a step closer to our goal of delivering a much-needed vaccine to help protect against Lyme disease. We are grateful to our partner Pfizer for their strong commitment which we both share in developing this vaccine as quickly as possible."

Juan Carlos Jaramillo, M.D., Valneva's Chief Medical Officer, underscored the urgent public health need, stating, "Lyme disease is the most prevalent vector-borne disease in the United States and Europe. It can result in debilitating complications and extensive healthcare treatments. Given the growing burden, high medical need, and lack of effectiveness with current interventions, there is an urgent need for novel approaches to help prevent Lyme disease." He also noted in November 2025 that final Phase 2 data confirmed the potential benefits of booster doses across all age groups, stating, "Lyme disease continues to expand geographically."

Lyme disease represents a significant public health concern, recognized as the most common vector-borne illness in the United States. The U.S. Centers for Disease Control and Prevention (CDC) estimates that approximately 476,000 individuals are diagnosed and treated for Lyme disease annually in the U.S., with an additional 132,000 cases reported each year in Europe. The disease can lead to debilitating complications, and currently, no approved human vaccines are available, making VLA15 the most advanced candidate in clinical development. Pfizer plans to submit a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in 2026, contingent on positive data. The success of these regulatory submissions will be crucial for Valneva's financial recovery and its mission to bring a much-needed preventative measure to market.